Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database.

Abstract

AIM:

To assess the prevalence of elevated liver enzymes and associated diabetes-related comorbidities in type 2 diabetes (T2D).

SUBJECTS AND METHODS:

Between 2010 and 2019, 281 245 patients with T2D (aged 18-75 years) from 501 Diabetes Prospective Follow-up (DPV) centres were evaluated, resulting in analysis of 51 645 patients with complete data on demographics and liver enzymes.

RESULTS:

Elevated liver enzymes were found in 40.2% of all patients. However, only 8.6% of these patients had International Classification of Diseases-10 codes for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Adjusted for age, sex, diabetes duration, body mass index and glycated haemoglobin, a higher prevalence of arterial hypertension (P < 0.0001), dyslipidaemia (P < 0.0001), peripheral artery disease (P = 0.0029), myocardial infarction (P = 0.0003), coronary artery disease (P = 0.0001), microalbuminuria (P < 0.0001) and chronic kidney disease (P < 0.0001) was seen in patients with elevated versus normal liver enzymes. The prevalence of elevated liver enzymes was lowest in patients receiving sodium-glucose cotransporter-2 (SGLT2) inhibitors or a combination of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists.

CONCLUSION:

Elevated liver enzymes are common in patients with T2D and clearly correlate with a higher prevalence of clinically relevant comorbidities. Assessing liver enzymes should be standard clinical routine in T2D due to a possible predictive role for comorbidities and complications.

• Authors: Svenja Meyhöfer, Alexander J Eckert, Michael Hummel, Markus Laimer, Michael Roden, Stephan Kress, Jochen Seufert, Sebastian M Meyhöfer, Reinhard W Holl
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 24 Issue 4 Pg. 727-732 (04 2022) ISSN: 1463-1326 [Electronic] England
• PMID: 34882949 (Publication Type: Letter, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 John Wiley & Sons Ltd.

Chemical References

• Hypoglycemic Agents
• Sodium-Glucose Transporter 2 Inhibitors

Topics

• Adolescent
• Adult
• Aged
• Diabetes Mellitus, Type 2 (complications, epidemiology)
• Follow-Up Studies
• Humans
• Hypoglycemic Agents
• Liver
• Middle Aged
• Non-alcoholic Fatty Liver Disease (complications, epidemiology)
• Prospective Studies
• Sodium-Glucose Transporter 2 Inhibitors
• Young Adult